Drug companies should target drug plans, rather than physicians, consultant says.
Silversides
Ann
A
D002170:Canada; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D010330:Patents as Topic